Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer-Reference-Cited by-同舟云学术

Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer

Published:1996-12-26 Issue:26 Volume:335 Page:1950-1955
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Alberts David S.,Liu P.Y.,Hannigan Edward V.,O'Toole Robert,Williams Stephen D.,Young James A.,Franklin Ernest W.,Clarke-Pearson Daniel L.,Malviya Vinay K.,DuBeshter Brent,Adelson Mark D.,Hoskins William J.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJM199612263352603

Cited by 1080 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

2. Nanomedicine-based targeting delivery systems for peritoneal cavity localized therapy: A promising treatment of ovarian cancer and its peritoneal metastasis;Chinese Chemical Letters;2024-07

3. 177Lu-FA-DOTA-PEG-PLGA Nanoparticles Show Antitumor Efficiency in Targeting Ovarian Cancer;Clinical and Experimental Obstetrics & Gynecology;2024-05-14

4. Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role;European Journal of Surgical Oncology;2024-04

5. Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial;Gynecologic Oncology;2024-02